Osborne Clarke in Amsterdam has advised the syndicate of investors on VarmX’s EUR 32 million Series B financing round. The round was co-led by Ysios Capital and INKEF Capital; Lundbeckfonden Ventures and LSP joined the syndicate.
Founding investor, BioGeneration Ventures (BGV) and the regional economic development fund, InnovationQuarter also participated in the round. VarmX is a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation.
VarmX will use the proceeds to achieve clinical proof of concept for lead compound, VMX-C001. It will also advance its program to registration studies, accelerate manufacturing trajectory towards commercial scale, and advance its discovery platform program.
The Osborne Clarke team in Amsterdam was led by Partner Herke van Hulst and included Senior Associate Marie-Louise Weeda and Associate Esser Turkyilmaz.
Osborne Clarke’s international life science and healthcare sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market. Recent notable work from the team in Amsterdam includes advising ViroClinics Biosciences on the acquisition of DDL Diagnostic Laboratory, assisting on the sale of Isobionics to BASF and the sale of Breath Therapeutics to Zambon last year.